Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...
Novo Nordisk ( NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its ...
Morgan Stanley analyst Terence Flynn notes that Novo Nordisk (NVO) reported CagriSema Phase 3 data in type two diabetes demonstrating weight ...
Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India, Brazil and ...
Rivaling Eli Lilly’s (NYSE:LLY) direct-to-consumer platform LillyDirect, which made its market debut last year, Novo Nordisk ...
In a report released today, Courtney Breen from Bernstein maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price ...
Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...
While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback